GlassScriptPhysician profile
Mihir D Buch
NPI 1124446026
$11,702.80
in general payments reported to CMS, 2019-2025
21 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $2,485 · 2021: $541 · 2022: $853 · 2023: $3,050 · 2024: $2,683 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,289 · Travel and Lodging: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,288.87 |
| Travel and Lodging | $1,307.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $4,381.15 | 2023-2025 | Galaxy |
| Covidien LP | $2,444.25 | 2020 | |
| Pulmonx Corporation | $1,590.09 | 2022-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Ethicon INC. | $1,529.82 | 2020-2024 | Monarch Platform |
| Boston Scientific Corporation | $307.79 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.67 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $198.25 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $176.14 | 2019-2024 | Nucala |
| Janssen Pharmaceuticals, INC | $139.65 | 2019-2021 | |
| Philips North America LLC | $136.41 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Genzyme Corporation | $134.59 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $111.55 | 2022-2024 | Dupixent |
| Insmed, INC. | $71.42 | 2020-2024 | Arikayce |
| Harmony Biosciences LLC | $65.69 | 2022-2023 | Wakix |
| Janssen Biotech, INC. | $52.21 | 2023-2024 | Rybrevant, Stelara, Simponi Aria |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.79 | 2025 | Tezspire |
| Electromed, INC. | $36.57 | 2025 | Smartvest |
| United Therapeutics Corporation | $19.92 | 2025 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $17.07 | 2022 | |
| Resmed Corp | $16.04 | 2023 | |
| Mylan Specialty L.P. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mihir Buch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.